- Home
- ARTL vs SXTP Comparison
ARTL vs SXTP Comparison
Compare ARTL & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTL
- SXTP
- Stock Information
- Founded
- ARTL 2011
- SXTP 2010
- Country
- ARTL United States
- SXTP United States
- Employees
- ARTL N/A
- SXTP N/A
- Industry
- ARTL Biotechnology: Pharmaceutical Preparations
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- ARTL Health Care
- SXTP Health Care
- Exchange
- ARTL Nasdaq
- SXTP Nasdaq
- Market Cap
- ARTL 3.1M
- SXTP 2.7M
- IPO Year
- ARTL N/A
- SXTP 2023
- Fundamental
- Price
- ARTL $1.05
- SXTP $2.61
- Analyst Decision
- ARTL Strong Buy
- SXTP Hold
- Analyst Count
- ARTL 2
- SXTP 1
- Target Price
- ARTL $5.50
- SXTP N/A
- AVG Volume (30 Days)
- ARTL 47.0K
- SXTP 43.8K
- Earning Date
- ARTL 05-13-2025
- SXTP 05-15-2025
- Dividend Yield
- ARTL N/A
- SXTP N/A
- EPS Growth
- ARTL N/A
- SXTP N/A
- EPS
- ARTL N/A
- SXTP N/A
- Revenue
- ARTL N/A
- SXTP $802,323.00
- Revenue This Year
- ARTL N/A
- SXTP $95.50
- Revenue Next Year
- ARTL N/A
- SXTP $80.78
- P/E Ratio
- ARTL N/A
- SXTP N/A
- Revenue Growth
- ARTL N/A
- SXTP 118.37
- 52 Week Low
- ARTL $0.82
- SXTP $1.41
- 52 Week High
- ARTL $1.55
- SXTP $35.99
- Technical
- Relative Strength Index (RSI)
- ARTL 58.55
- SXTP 54.44
- Support Level
- ARTL $0.90
- SXTP $1.95
- Resistance Level
- ARTL $1.14
- SXTP $2.74
- Average True Range (ATR)
- ARTL 0.07
- SXTP 0.21
- MACD
- ARTL 0.01
- SXTP 0.04
- Stochastic Oscillator
- ARTL 62.23
- SXTP 83.02
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.